Arcutis Biotherapeutics Inc has a consensus price target of $29.08, established from looking at the 47 latest analyst ratings. The last 3 analyst ratings were released from Needham, Goldman Sachs, and Mizuho on April 12, 2024, February 28, 2024, and February 28, 2024. With an average price target of $14.67 between Needham, Goldman Sachs, and Mizuho, there's an implied 45.21% upside for Arcutis Biotherapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/12/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 58.42% | Needham | Serge Belanger | → $16 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 8.91% | Goldman Sachs | Jonathan Block | $6 → $11 | Maintains | Neutral | Get Alert |
02/28/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 68.32% | Mizuho | Uy Ear | $16 → $17 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 58.42% | Needham | Serge Belanger | $8 → $16 | Maintains | Buy | Get Alert |
02/23/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 58.42% | Mizuho | Uy Ear | $8 → $16 | Reiterates | Buy → Buy | Get Alert |
01/03/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -20.79% | Mizuho | Uy Ear | $4 → $8 | Upgrade | Neutral → Buy | Get Alert |
01/02/2024 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -20.79% | Mizuho | Uy Ear | $4 → $8 | Upgrade | Neutral → Buy | Get Alert |
11/13/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -0.99% | Morgan Stanley | Nigel Dally | $45 → $10 | Maintains | Overweight | Get Alert |
11/08/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | — | JonesTrading | Sean Kim | — | Downgrade | Buy → Hold | Get Alert |
11/06/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -20.79% | Needham | Serge Belanger | $22 → $8 | Maintains | Buy | Get Alert |
11/06/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -20.79% | HC Wainwright & Co. | Serge Belanger | $22 → $8 | Maintains | Buy | Get Alert |
10/27/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -60.4% | Mizuho | Uy Ear | $57 → $4 | Downgrade | Buy → Neutral | Get Alert |
10/13/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | -40.59% | Goldman Sachs | Jonathan Block | $32 → $6 | Downgrade | Buy → Neutral | Get Alert |
09/25/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 464.36% | Mizuho | Uy Ear | → $57 | Reiterates | Buy → Buy | Get Alert |
08/22/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 395.05% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
08/10/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 117.82% | Needham | Serge Belanger | → $22 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 395.05% | TD Cowen | Ken Cacciatore | $65 → $50 | Maintains | Outperform | Get Alert |
07/18/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 137.62% | Needham | Serge Belanger | → $24 | Reiterates | Buy → Buy | Get Alert |
06/28/2023 | ARQT | Buy Now | Arcutis Biotherapeutics | $10.10 | 395.05% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
The latest price target for Arcutis Biotherapeutics (NASDAQ: ARQT) was reported by Needham on April 12, 2024. The analyst firm set a price target for $16.00 expecting ARQT to rise to within 12 months (a possible 58.42% upside). 26 analyst firms have reported ratings in the last year.
The latest analyst rating for Arcutis Biotherapeutics (NASDAQ: ARQT) was provided by Needham, and Arcutis Biotherapeutics reiterated their buy rating.
The last upgrade for Arcutis Biotherapeutics Inc happened on January 3, 2024 when Mizuho raised their price target to $8. Mizuho previously had a neutral for Arcutis Biotherapeutics Inc.
The last downgrade for Arcutis Biotherapeutics Inc happened on November 8, 2023 when JonesTrading changed their price target from N/A to N/A for Arcutis Biotherapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcutis Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcutis Biotherapeutics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
While ratings are subjective and will change, the latest Arcutis Biotherapeutics (ARQT) rating was a reiterated with a price target of $0.00 to $16.00. The current price Arcutis Biotherapeutics (ARQT) is trading at is $10.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.